000298938 001__ 298938
000298938 005__ 20251125084725.0
000298938 0247_ $$2doi$$a10.1002/ijc.35345
000298938 0247_ $$2pmid$$apmid:39945620
000298938 0247_ $$2ISSN$$a0020-7136
000298938 0247_ $$2ISSN$$a1097-0215
000298938 037__ $$aDKFZ-2025-00372
000298938 041__ $$aEnglish
000298938 082__ $$a610
000298938 1001_ $$aLehtinen, Matti$$b0
000298938 245__ $$aScientific approaches to defining HPV vaccine-induced protective immunity.
000298938 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000298938 3367_ $$2DRIVER$$aarticle
000298938 3367_ $$2DataCite$$aOutput Types/Journal article
000298938 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764056796_3576553$$xReview Article
000298938 3367_ $$2BibTeX$$aARTICLE
000298938 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298938 3367_ $$00$$2EndNote$$aJournal Article
000298938 500__ $$aDivision of Infections and Cancer,Deutsches Krebsforschungszentrum, /  2025 May 15;156(10):1848-1857 / AG Martin Müller
000298938 520__ $$aSeventeen years after the licensure of prophylactic human papillomavirus (HPV) L1 virus-like-particle vaccines, a defined antibody level that correlates with vaccine-induced protection against HPV infections and associated neoplasia is missing. In contrast, correlates of protection have been defined for many viral vaccines, including for the hepatitis B virus (HBV) vaccine. This review includes lessons learned from vaccination against HBV and the use of an established protective HBV surface antigen antibody level: 10 mIU/mL, an overview of HPV infection-induced and HPV vaccine-induced antibody responses, successful efforts to establish international standardization of serological reagents and associated tools, and 15-year vigilance of HPV vaccine-induced antibody levels in a vaccination cohort against breakthrough infections. This report identifies progress but also gaps on the journey toward the definition of a HPV vaccine-induced correlate of protection.
000298938 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000298938 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000298938 650_7 $$2Other$$aantibody
000298938 650_7 $$2Other$$acancer
000298938 650_7 $$2Other$$ahepatitis B virus
000298938 650_7 $$2Other$$ahuman papillomavirus
000298938 650_7 $$2Other$$avaccine
000298938 7001_ $$avan Damme, Pierre$$b1
000298938 7001_ $$aBeddows, Simon$$b2
000298938 7001_ $$aPinto, Ligia A$$b3
000298938 7001_ $$0P:(DE-HGF)0$$aMariz, Filipe$$b4
000298938 7001_ $$00000-0001-9065-4734$$aGray, Penelope$$b5
000298938 7001_ $$00000-0001-8588-6506$$aDillner, Joakim$$b6
000298938 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.35345$$gp. ijc.35345$$n10$$p1848-1857$$tInternational journal of cancer$$v156$$x0020-7136$$y2025
000298938 909CO $$ooai:inrepo02.dkfz.de:298938$$pVDB
000298938 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000298938 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000298938 9141_ $$y2025
000298938 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-17$$wger
000298938 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-17$$wger
000298938 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000298938 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000298938 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000298938 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-17
000298938 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000298938 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-17
000298938 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-17
000298938 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000298938 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000298938 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2024-12-17
000298938 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2024-12-17
000298938 9201_ $$0I:(DE-He78)D335-20160331$$kD335$$lTumorvirus-spez. Vakzinierungsstrategie$$x0
000298938 980__ $$ajournal
000298938 980__ $$aVDB
000298938 980__ $$aI:(DE-He78)D335-20160331
000298938 980__ $$aUNRESTRICTED